Business, Policy & Funding
Breaking news on precision medicine business, policy & funding.
FDA Approves Entrogen's RAS Mutation Detection Kit as CDx for Vectibix
The test, intended for use with Amgen's Vectibix, detects KRAS and NRAS exon 2, 3, and 4 mutations in colorectal cancer patients.
Eli Lilly to Acquire Radiopharmaceutical Firm Point Biopharma for $1.4 Billion
The deal brings Lilly a pipeline of targeted radioligands being evaluated for certain prostate cancer and neuroendocrine cancer patients, among others.
Takeda to Withdraw Exkivity Accelerated Approval in EGFR-Mutant NSCLC in US, Globally
The firm said the Phase III confirmatory trial of Exkivity in first-line EGFR exon 20 insertion-positive advanced NSCLC did not meet its primary endpoint.
BostonGene, Johns Hopkins University Partner for Multiple Cancer Clinical Research Projects
The partners plan to analyze patients' tumors, immune systems, and tumor microenvironments to predict treatment response and identify targetable molecular alterations.
ProciseDx Gets US Marketing Clearance for Infliximab, Adalimumab POC Monitoring Tests
The firm plans this year to launch in the US its tests used to measure drug levels in inflammatory bowel disease patients and guide treatment.